Is the future bright for diabetes?

Southern Medical Journal

Volumn 97, Issue 11, 2004, Pages 1027-1028

  Bond, Michael M ^a   Yates, Scott W ^a  

^a North Texas Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE; INSULIN; INSULIN DERIVATIVE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PRAMLINTIDE; TESAGLITAZAR; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; EDITORIAL; EPIDEMIC; HUMAN; HYPERINSULINEMIA; INSULIN PUMP; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; FORECASTING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; THIAZOLIDINEDIONES;

EID: 8744299422     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000140860.95540.F8     Document Type: Editorial

References (16)

1. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. New Engl J Med 1989;321:337-341.
2. Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000;21:585-618.
3. Ferrannini, E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19:477-490.
4. Hu G, Lindstrom M, Valle T, et al. Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. Arch Intern Med 2004;164:892-896.
5. Diabetes Prevention Research Group. Reduction in the evidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med 2002;346:393-403.
6. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-957.
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
8. Putzer G, Ramirez A, Sneed K, et al. Prevalence of patients with type 2 diabetes mellitus reaching the American Diabetes Association's target guidelines in a university primary care setting. South Med J 2004;97:145-148.
9. Rizvi AA. Type 2 diabetes: epidemiologic trends, evolving pathogenic concepts, and recent changes in therapeutic approach. South Med J 2004;11:1079-1087.
10. Anonymous. New chemical entities and line extensions [AstraZeneca International Web site]. Available at http://www.astrazeneca.com/article/ 501216.aspx.
11. Anonymous. Symlin (pramlintide acetate) [Amylin Pharmaceuticals Web site]. Available at http://www.amylin.com/Pipeline/Symlin.cfm.
12. Anonymous. Exenatide (synthetic exendin-4) [Amylin Pharmaceuticals Web site]. Available at http://www.amylin.com/Pipeline/AC2993.cfm.
13. Zander M, Madsbad S, Madsen JL and Holst JJ. Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 9 March 2002;359:9309.
14. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schwiezer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucaton levels in type 2 diabetes. J Clin Endocrinol Metab May 2004;89(5):2078-84.
15. Anonymous. Product candidates: oral insulin [Emisphere Technologies, Inc. Web site]. Available at http://www.emisphere.com/pc_oi.asp.
16. Anonymous. Aradigm and Novo Nordisk release interim analysis of initial pulmonary insulin phase 3 trial. Available at http://ir.thomsonfn.com/ InvestorRelations/PubNewsStory.aspx?partner=7677&storyId=113007.